Markets:

Overview

News

Currencies

International

Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

3.860 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >

AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday? ↗

November 07, 2025

Risk-off sentiment dominated Wall Street on Friday, with selling pressure in AI-linked names intensifying and pushing technology stocks toward their worst week since April.

Via Benzinga

Topics Artificial Intelligence

AbCellera Biologics Inc (NASDAQ:ABCL) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗

November 06, 2025

AbCellera's Q3 2025 results show revenue beat estimates, but the net loss widened, causing a negative after-hours stock reaction.

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Earnings Scheduled For February 27, 2025 ↗

February 27, 2025

Via Benzinga

AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? ↗

November 06, 2025

After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto...

Via Benzinga

Topics Artificial Intelligence

Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus ↗

October 02, 2025

U.S. stock futures were fluctuating on Thursday following Wednesday's record advances. Futures of major benchmark indices were mixed.

Via Benzinga

Topics Stocks

Why Did AbCellera's Stock Jump Over 7% After Hours? ↗

October 02, 2025

AbCellera's stock rose 7.72% in after-hours trading following an 18.49% gain during regular trading, with a strong performance expected in Q3 earnings.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 18, 2025

Via Benzinga

Expert Outlook: AbCellera Biologics Through The Eyes Of 4 Analysts ↗

August 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 08, 2025

Via Benzinga

AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript ↗

August 08, 2025

Via The Motley Fool

Topics Earnings

Curious about the stocks that are showing activity after the closing bell on Thursday? ↗

August 07, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday ↗

July 21, 2025

Via Benzinga

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today ↗

June 02, 2025

Via The Motley Fool

AbCellera Biologics (ABCL) Q4 2024 Earnings Call Transcript ↗

February 27, 2025

ABCL earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

AbCellera Biologics (ABCL) Q3 2024 Earnings Call Transcript ↗

November 04, 2024

ABCL earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week ↗

September 15, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual...

Via Talk Markets

AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗

September 10, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual...

Via Talk Markets

Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! ↗

September 05, 2024

The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug...

Via Talk Markets

Topics Economy

Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week ↗

August 27, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030.

Via Talk Markets

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

August 20, 2024

Via Benzinga

AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD ↗

August 14, 2024

The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion...

Via Talk Markets

AbCellera Biologics (ABCL) Q2 2024 Earnings Call Transcript ↗

August 07, 2024

ABCL earnings call for the period ending June 30, 2024.

Via The Motley Fool

Topics Earnings

AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD ↗

July 30, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030.

Via Talk Markets

"Bubble" In AI/Semiconductor Stocks Began To Re-Inflate On Friday ↗

July 28, 2024

A week ago it was suggested that the AI/semiconductor stocks sector was oversold. The decline bottomed on Wednesday and by the close of business this past Friday the sector had rebounded nicely almost...

Via Talk Markets

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio? ↗

July 21, 2024

The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.

Via The Motley Fool

AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD ↗

July 18, 2024

To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under...

Via Talk Markets

Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗

July 14, 2024

The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.